Legal & General Group
AVTX icon

Legal & General Group’s Avalo Therapeutics AVTX Stock Holding History

Legal & General Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed -$2K – 3456
2022
Q2 		$2K Sell
1
-1
-50% -$1.34K ﹤0.01% 3486
2022
Q1 		$4K Hold
2
– – ﹤0.01% 3516
2021
Q4 		$9K Hold
2
– – ﹤0.01% 3473
2021
Q3 		$12K Hold
2
– – ﹤0.01% 3408
2021
Q2 		$18K Buy
2
+1
+100% +$8.38K ﹤0.01% 3321
2021
Q1 		$13K Sell
1
-1
-50% -$9.45K ﹤0.01% 3293
2020
Q4 		$13K Hold
2
– – ﹤0.01% 3235
2020
Q3 		$11K Hold
2
– – ﹤0.01% 3188
2020
Q2 		$12K Buy
2
+1
+100% +$7.26K ﹤0.01% 3256
2020
Q1 		$8K Sell
1
-1
-50% -$10.6K ﹤0.01% 3195
2019
Q4 		$24K Buy
2
+1
+100% +$10.5K ﹤0.01% 3127
2019
Q3 		$12K Hold
1
– – ﹤0.01% 3239
2019
Q2 		$18K Buy
+1
New +$15.2K ﹤0.01% 3233

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Legal & General Group's AVTX Position: Q3 2022 in Review

Legal & General Group sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 1 share — an estimated $2K sold.

Legal & General Group first reported a position in AVTX in Q2 2019 and held it in 13 quarters. The position peaked at $24K in Q4 2019. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Legal & General Group reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 1 Avalo Therapeutics share in Q3 2022, an estimated $2K.
  • Legal & General Group first reported a position in Avalo Therapeutics in Q2 2019 and held it in 13 quarters.
  • Legal & General Group's Avalo Therapeutics position peaked at $24K in Q4 2019.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.